Genzyme and AnorMED Announce Completion of Hart-Scott-Rodino Review

CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7  /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) announced today the expiration of the waiting period under the Hart-Scott- Rodino Antitrust Improvements Act of 1976 with respect to Genzyme's tender offer to acquire the outstanding shares of AnorMED.

Genzyme and AnorMED announced on October 17, 2006 that they had entered into a support agreement pursuant to which Genzyme expects to acquire AnorMED in an all cash transaction valued at $13.50 per outstanding share, or approximately $580 million.  Genzyme's offer is set to expire today at 8:00 a.m. Vancouver time.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th anniversary of Genzyme's founding.  Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,500 employees in locations spanning the globe and 2005 revenues of $2.7 billion.  Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.

Important Information Regarding the Tender Offer

Investors and security holders are urged to read the disclosure documents filed with the Securities and Exchange Commission (the "SEC") from time to time, including the tender offer statement filed on September 1, 2006, as amended, regarding the tender offer by Genzyme's wholly owned subsidiary, Dematal Corp., for all of the outstanding common shares of AnorMED. Investors and security holders may obtain a free copy of the disclosure documents and other documents filed by Genzyme or Dematal with the SEC at the SEC's website at http://www.sec.gov/. In addition, documents filed with the SEC by Genzyme or Dematal may be obtained free of charge from Genzyme by directing a request to Sally Curley at [phone].

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com/ and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.

  CONTACTS:

  For AnorMED                              For Genzyme
  Kenneth Galbraith (investors)            Sally Curley (investors)
  [phone]                           [phone]

  Karen Cook Boas (media)                  Dan Quinn (media)
  [phone]                           [phone]


DATASOURCE: Genzyme Corporation



CONTACT:  Kenneth Galbraith (investors), [phone], or Karen Cook

Boas (media), [phone], both For AnorMED; or Sally Curley (investors),

[phone], or Dan Quinn (media), [phone], both for Genzyme



Web site:  http://www.genzyme.com/



Company News On-Call:  http://www.prnewswire.com/comp/104284.html

Copyright